Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
Lancet Infect Dis
; 21(9): 1271-1281, 2021 09.
Article
in En
| MEDLINE
| ID: mdl-33989539
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hepatitis B Vaccines
/
Immunogenicity, Vaccine
/
Hepatitis B
/
Hepatitis B Antibodies
/
Antigens, Viral
Type of study:
Clinical_trials
/
Guideline
Limits:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
/
Asia
/
Europa
Language:
En
Journal:
Lancet Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2021
Document type:
Article
Affiliation country:
Finlandia